U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
  • Quoted phrase not found.
  • See the search details.
Nirmatrelvir-Ritonavir (Paxlovid): CADTH Reimbursement Recommendation: Indication: For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death [Internet].

Nirmatrelvir-Ritonavir (Paxlovid): CADTH Reimbursement Recommendation: Indication: For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.

Table of contents

1.

Nirmatrelvir-Ritonavir (Paxlovid): CADTH Reimbursement Recommendation: Indication: For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death [Internet].

Supplemental Content

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...